Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hemispherx Forms Partnership in Saudi Arabia | Contract Pharma

What are you searching for?

Sign in
Breaking News

Hemispherx Forms Partnership in Saudi Arabia

Enters into alfa-n3 interferon clinical trial, sales, marketing, distribution and supply agreement.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hemispherx Biopharma has entered into a clinical trial, sales, marketing, distribution and supply agreement with Scientific Products Pharmaceutical (SCIEN) located in Riyadh, Saudi Arabia. The contract covers Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain, expanding Hemispherx’s early access programs (EAP) globally.

The agreement also calls for SCIEN to purchase certain quantities of Hemispherx’s clinical grade interferon alfa-n3 for investigative use in individuals who are exposed to and show early onset symptoms of the coronavirus that causes MERS. MERS was first identified in Saudi Arabia in 2012, and can cause severe acute respiratory illness with symptoms of fever, cough, and shortness of breath as well as death.

“We are grateful to be able to undertake this important project with Saudi Arabia’s premiere pharma company,” said Tom Equels, chief executive officer, Hemispherx Biopharma. “This is the natural next step to our successful orphan drug designation in the EU regarding Alferon as a therapy for MERS, a deadly virus, for which there is no currently approved therapy.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics